HORSHAM, Pa. -- (BUSINESS WIRE) -- Acurian, Inc., a leading, full-service provider of global patient enrollment and retention solutions, announced today that it has enhanced its partnership with the Society for Clinical Research Sites (SCRS) by sponsoring the SCRS monthly webinar series through June 2014.
The SCRS is the first organization fully dedicated to representing the interests of the clinical research site community, enabling members to participate in discussions and decisions that ultimately impact the clinical research sites and the industry at large. Acurian, along with its parent company PPD, joined the SCRS as a Global Impact Partner in 2013, a designation which includes executive-level participation on the SCRS Global Impact Board.
As part of the new sponsorship agreement, Acurian will also host an SCRS webinar entitled “Learn How to Get the Most out of Your Recruitment Provider: Leveraging the Benefits of a Centralized Recruitment Program.” The webinar, scheduled for April 8, 2014, will include results of a quantitative survey that provides current insight into site perceptions surrounding patient recruitment, and opportunities for improving patient enrollment across all clinical stakeholders.
“As part of Acurian’s ongoing commitment to SCRS, we are excited to be sponsoring the webinar series and hosting our own webinar to the SCRS audience,” stated Rick Malcolm, Executive Vice President and General Manager, Acurian. “We welcome this opportunity to communicate directly with sites and raise awareness of the benefits of patient enrollment organizations.”
“Acurian is a charter Global Impart Partner, which is a major commitment to SCRS,” commented Christine Pierre, SCRS President. “Its ongoing support, including sponsorship of our webinar series, enables us to broaden our reach and expand the program as needed within the site community.”
The SCRS webinar series features topics in GBP (Good Business Practices) and GCP (Good Clinical Practices). SCRS members receive access and CEU credits to all these webinars as part of their membership benefits package.
Acurian, a subsidiary of PPD, is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time.
SCRS is a trade organization of global clinical research sites that has grown to over 1,300 sites in 22 countries since its launch in October 2013. SCRS' mission is to unify and amplify the voice of the global clinical research site community for site sustainability. SCRS has become an active partner in industry-wide dialogues focused on improving the clinical research enterprise among the many industry initiatives. Sites, as well as companies that sponsor or support the work conducted at the clinical research sites, will also benefit from membership.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Acurian’s patient enrollment and engagement services, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: rapid technological advances that make our services less competitive; competition in the outsourcing industry; the ability to attract, integrate and retain key personnel; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD’s ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.